Henar Calvo‐Sánchez

Henar Calvo‐Sánchez

Auto-generated profile, based on publicly available information

Henar Calvo‐Sánchez

Service of Gastroenterology University Hospital of Guadalajara Guadalajara Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2026 in Liver International
Verified
Journal Article
Open access
PDF file
HCHenar Calvo‐Sánchez
Henar Calvo‐Sánchez
LJLorena Jara‐Fernández
Lorena Jara‐Fernández
RERaquel Encijo‐Heredia
Raquel Encijo‐Heredia
IVIrene Villarino
Irene Villarino
RARubén Alvarado
Rubén Alvarado
JLJuan Larrubia
Juan Larrubia
Background: Although sustained virological response (SVR) after hepatitis C virus treatment reduces hepatocellular carcinoma (HCC) incidence, residual risk persists. Metformin has been associated with lower HCC risk, but whether cumulative metformin exposure (CME) lowers post‐SVR risk remains unclear. We evaluated whether CME was associated with lower HCC risk after SVR. Methods: We analysed a multicentre cohort of 1531 patients who achieved SVR after direct‐acting antiviral therapy (median follow‐up, 75.5 months). Metformin exposure was modelled as a time‐updated cumulative variable in start–stop Cox models to control for immortal‐time bias. Stabilised inverse probability weighting addressed confounding by indication and censoring. The overall model was sex‐stratified and adjusted for FIB‐4, clinically significant portal hypertension (CSPH), type 2 diabetes mellitus (T2DM) and smoking. A prespecified T2DM‐restricted analysis used T2DM‐specific IPTW plus IPCW, sex stratification and CSPH adjustment. Results: During follow‐up, 50 patients developed HCC. Crude incidence was highest among patients with FIB‐4 > 3.25, CSPH and T2DM without metformin exposure (4.84 cases per 100 person‐years). In the overall weighted model, CME was associated with lower HCC risk (HR, 0.46 per year; 95% CI, 0.27–0.77; p = 0.004). CSPH, T2DM, smoking and FIB‐4 > 3.25 independently increased risk. In the T2DM‐restricted model, each additional year remained associated with lower HCC hazard (HR, 0.49; 95% CI, 0.29–0.84; p = 0.009), whereas CSPH was associated with higher risk (HR, 6.04; 95% CI, 2.12–17.19; p < 0.001). Conclusion: After SVR, CME was associated with lower HCC risk; this possible duration‐dependent inverse association was clinically interpretable only among metformin‐eligible patients with T2DM.

27 September 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
JPJulia Pena-Asensio
Julia Pena-Asensio
HCHenar Calvo
Henar Calvo
JMJoaquín Miquel
Joaquín Miquel
ESEduardo Sanz‐De‐Villalobos
Eduardo Sanz‐De‐Villalobos
AGAlejandro González‐Praetorius
Alejandro González‐Praetorius
JLJuan Larrubia
Juan Larrubia

5 November 2026 in Liver International
Verified
Journal Article
Closed access
PDF file
HCHenar Calvo‐Sánchez
Henar Calvo‐Sánchez
LJLorena Jara‐Fernández
Lorena Jara‐Fernández
CFConrado Fernández‐Rodríguez
Conrado Fernández‐Rodríguez
JLJuan Larrubia
Juan Larrubia